Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
The availability of advanced SLED dialysis for critical patients, Plasmapheresis, CRRT machines along with ICCU dialysis complete the centre in every way
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
The product will be manufactured at Lupin’s facility in Pithampur, India
The phosphine ligand is available on the kilo scale for the first time, providing scientists with a powerful solution for cross-coupling chemistry
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
At the new centre, customers get a real-time experience of the process of genetic testing and actionable plans in preventive healthcare under the expertise of certified genetic counsellors
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
Subscribe To Our Newsletter & Stay Updated
